Drug Trial Radar · NCT01657604
TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
Last checked: Nov 19, 2026Latest source record: May 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
717
Actual
Start
Aug 24, 2012
Primary completion
May 31, 2022
Study completion May 31, 2022
Sponsor
- Lead sponsor
- University of JenaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 6, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Advances in Chronic Myeloid Leukemia (CML) therapy led to an expected survival prolongation of \> 20 years after diagnosis. So far, discontinuation of tyrosine kinase inhibitors led to recurrence of disease in the majority of patients. The trial aims to improve treatment strategies in CML by improving induction therapy and deescalating maintenance therapy using low dose IFN as inducer of immunosurveillance. The trial will provide important data on the duration of active therapy in CML patients. Considering the rapidly increasing prevalence of CML this is of individual but also socioeconomic importance.
Conditions
- Chronic Myeloid Leukemia
Interventions
Peginterferon α2bDrug
Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with at a starting target dose of 30μg/week. After confirmed MMR or at least 24 mo. after start of therapy, maintenance therapy (nilotinib will be discontinued) will start for a study duration of up to 5 years.
NilotinibDrug
Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily for a study duration of up to 5 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- MMR rate at 18 months of nilotinib monotherapy versus nilotinib+pegylated interferon alphaTime frame: at least 18 months after start of study treatment
- rate of continuous MMR after discontinuation of nilotinib versus pegylated interferon alphaTime frame: at least 12 months after stopping all therapy
Locations
112 sites in 3 countries. Site status is shown where the registry gives one.
University Hospital and Masaryk University Brno
Brno, Czechia
Universitätsklinikum Aachen Medizinische Klinik IV
Aachen, Germany
Gesundheitszentrum St. Marien GmbH, Onkologie/ Hämatologie Onkologisches Zentrum
Amberg, Germany
MVZ am Klinikum Arnsberg GmbH, Hämatologie - Internistische Onkologie
Arnsberg, Germany
Studienzentrum Drs. Klausmann
Aschaffenburg, Germany
Klinikum Augsburg
Augsburg, Germany
Klinikum Bayreuth GmbH
Bayreuth, Germany
Vivantes Netzwerk für Gesundheit GmbH, Klinikum Neukölln, Klinik für Innere Medizin - Hämatologie und Onkologie
Berlin, Germany
Charité CVK, CC14, Klinik für Hämatologie und Onkologie
Berlin, Germany
Evangelisches Klinikum Bethel
Bielefeld, Germany
Universitätsklinikum Bonn Med. Klinik und Poliklinik III, Hämatologie
Bonn, Germany
Zentrum für Ambulante Hämatologie und Onkologie
Bonn, Germany
Städtisches Klinikum Braunschweig gGmbh, Medizinische Klinik III - Hämatologie
Braunschweig, Germany
Klinikum Bremen-Mitte gGmbH
Bremen, Germany
DIAKO Ev. Diakonie-Krankenhaus gGmbH, Medizinische Klinik II
Bremen, Germany
Klinikum Chemnitz gGmbH Klinik für Innere Medizin III
Chemnitz, Germany
Universitätsklinikum Köln
Cologne, Germany
Onkologische Schwerpunktpraxis
Dresden, Germany
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
Dresden, Germany
Onkologisch-Hämatologische Schwerpunktpraxis
Eisenach, Germany
Dr. med. Ulrich Hauch
Erfurt, Germany
Onkologische Schwerpunktpraxis Erlangen, Onkologie, Hämatologie
Erlangen, Germany
Universitätsklinikum Erlangen Medizinische Klinik 5 - Hämatologie und int. Onkologie
Erlangen, Germany
St.-Antonius-Hospital, Klinik für Hämatologie Onkologie
Eschweiler, Germany
Klinik für Hämatologie Universitätsklinikum Essen
Essen, Germany
Klinikum der Goethe Universität
Frankfurt, Germany
Universitätsklinikum Freiburg Abteilung Innere Medizin I - Hämatologie und Onkologie
Freiburg im Breisgau, Germany
MVZ-Osthessen GmbH Klinikum Fulda Tumorklinik
Fulda, Germany
Praxis Dr. med. Schmitt
Gerlingen, Germany
Dr. med. Hans Werner Tessen, Facharzt für Innere Medizin
Goslar, Germany
Georg-August Universität Göttingen Abteilung Hämatologie und Onkologie
Göttingen, Germany
Universitätsmedizin Greifswald, Klinik und Poliklinik für Innere
Greifswald, Germany
Internistische Gemeinschaftspraxis
Güstrow, Germany
Katholisches Krankenhaus Hagen gem. GmbH, Klinik für Hämatologie und
Hagen, Germany
Gemeinschaftspraxis Hämatologie und internistische
Halle, Germany
Universitätsklinikum Halle (Saale)
Halle, Germany
Asklepios Klinik St. Georg, Abteilung Hämatologie, Onkologie, Stammzelltransplantation
Hamburg, Germany
Universitätsklinikum Hamburg- Eppendorf, Medizinische Klinik 2
Hamburg, Germany
Evangelisches Krankenhaus Hamm
Hamm, Germany
St. Barbara-Klinik, Standort St. Josef
Hamm, Germany
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.